US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

10.05

+1.5117.68%

Post-market: 9.70-0.3500-3.48%19:57 EDT

Volume:841.68K

Turnover:8.16M

Market Cap:546.79M

PE:-0.64

High:10.49

Open:8.48

Low:8.45

Close:8.54

Loading ...

Overview Company News Filings

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Is Maintained at Buy by HC Wainwright & Co.

Alumis price target lowered to $26 from $30 at H.C. Wainwright

Alumis Q3 EPS $(1.73) Beats $(4.50) Estimate

Press Release: Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Baird Initiates Alumis at Outperform With $25 Price Target

MT Newswires Live

Alumis Initiated at Outperform by Baird

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

HC Wainwright Initiates Coverage on Alumis With Buy Rating, $30 Price Target

MT Newswires Live

Alumis initiated with a Buy at H.C. Wainwright

Alumis Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $30

THOMSON REUTERS

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":10.05,"timestamp":1743796800000,"preClose":8.54,"halted":0,"volume":841681,"hourTrading":{"tag":"盘后","latestPrice":9.7,"preClose":10.05,"latestTime":"19:57 EDT","volume":2140,"amount":20605.5398,"timestamp":1743811071782},"delay":0,"floatShares":19951689,"shares":54407327,"eps":-15.598233,"marketStatus":"Market Closed","change":1.51,"latestTime":"04-04 16:00:00 EDT","open":8.48,"high":10.49,"low":8.45,"amount":8164243.4156059995,"amplitude":0.238876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-15.598233,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":8.54,"preHourTrading":{"tag":"盘前","latestPrice":8.449,"preClose":8.54,"latestTime":"09:28 EDT","volume":1402,"amount":11794.634842,"timestamp":1743773292273},"postHourTrading":{"tag":"盘后","latestPrice":9.7,"preClose":10.05,"latestTime":"19:57 EDT","volume":2140,"amount":20605.5398,"timestamp":1743811071782},"volumeRatio":0.615526},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":19951689,"roa":"-87.31%","roe":"-198.66%","lyrEps":-72.082961,"volumeRatio":0.615526,"shares":54407327,"dividePrice":0,"high":10.49,"amplitude":0.238876,"preClose":8.54,"low":8.45,"week52Low":3.18,"pbRate":"2.10","week52High":13.53,"institutionHeld":0,"latestPrice":10.05,"eps":-15.598233,"divideRate":0,"volume":841681,"delay":0,"ttmEps":-15.598233,"open":8.48,"prevYearClose":7.86,"prevWeekClose":5.64,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":5.64,"twentyDayClose":4.88,"sixtyDayClose":8.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2483258337","title":"Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483258337","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483258337?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981606/0/en/Alumis-Presents-Data-Highlighting-ESK-001-s-Potential-as-a-High-efficacy-Oral-Treatment-for-Systemic-Lupus-Erythematosus-SLE-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4007","ALMS","ACR","BK4077","BK4110"],"gpt_icon":0},{"id":"2483131878","title":"Alumis Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483131878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483131878?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:24","pubTimestamp":1731583440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 06:24 ET (11:24 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2483878597","title":"Alumis price target lowered to $26 from $30 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2483878597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483878597?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:15","pubTimestamp":1731582927,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $26 from $30 and keeps a Buy rating on the shares following the Q3 report. Publ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-26-from-30-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-26-from-30-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2483863203","title":"Alumis Q3 EPS $(1.73) Beats $(4.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863203","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863203?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:34","pubTimestamp":1731533690,"startTime":"0","endTime":"0","summary":"Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.73) per share which beat the analyst consensus estimate of $(4.50) by 61.56 percent. This is a 91.24 percent increase over losses of $(19.76) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41955982/alumis-q3-eps-1-73-beats-4-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Alumis Q3 EPS $(1.73) Beats $(4.50) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2483141868","title":"Press Release: Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2483141868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483141868?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"-- Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition --. -- Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus  and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases --. SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4007","LU1989772923.USD","LU1162221912.USD","LU0314104364.USD","ACR","BK4077","LU1720051108.HKD","LU1363072403.SGD","IE00BKVL7J92.USD","LU1989772840.SGD","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1668664300.SGD","BK4516","BK4585","BK4110","BK4127","BK4135","BK4581","LU0267386448.USD","LU0971096721.USD","LU0098860793.USD","LU0225283273.USD","LU0006306889.USD","ALMS","BK4588","LU0106261372.USD","LU0320765646.SGD","BK4534","LU0106831901.USD","SLE","BK4504","LU1074936037.SGD","LU2357305700.SGD","LU1548497426.USD"],"gpt_icon":0},{"id":"2480300355","title":"Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300355","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300355?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 2:00 pm ET in Boston, MA.A live webcast will be available on the Alumis website in the \"Investors\" section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.Forward Looking StatementsThis press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming con","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2NYpvYmuqK3WlAh7C3b9IQ--~B/aD0zOTt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6eb34a25d74ca457b5b279aeaabcd69c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2NYpvYmuqK3WlAh7C3b9IQ--~B/aD0zOTt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6eb34a25d74ca457b5b279aeaabcd69c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-participate-guggenheims-inaugural-healthcare-130000488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALMS","BK4007","HCSG","BK4137"],"gpt_icon":0},{"id":"2479089050","title":"Baird Initiates Alumis at Outperform With $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2479089050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479089050?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:41","pubTimestamp":1730378492,"startTime":"0","endTime":"0","summary":"Baird Initiates Alumis at Outperform With $25 Price Target","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS"],"gpt_icon":0},{"id":"2479834703","title":"Alumis Initiated at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2479834703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479834703?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:08","pubTimestamp":1730369280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 06:08 ET (10:08 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2476829844","title":"Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2476829844","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476829844?lang=en_us&edition=fundamental","pubTime":"2024-10-18 02:32","pubTimestamp":1729189931,"startTime":"0","endTime":"0","summary":"HC Wainwright has initiated coverage on Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2  inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis  and in Phase 2 trials for systemic lupus erythematosus . HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30.Also Read: Newly-Listed Psoriasis-Focused Alumis Attracts Analysts’ Attention With Promising Lead Program And Modest Valuation.According to HC Wainwright, ESK-001 boasts the highest selectivity within the TYK2 inhibitor space, outperforming Bristol Myers Squibb & Co’s  approved drug, Sotyktu  and Takeda Pharmaceutical Co Ltd’s  Phase 3 candidate, TAK-279.While Sotyktu currently leads the TYK2 market, HC Wainwright emphasizes that clinical data for ESK-001 suggest a significantly superior profile, which could drive substantial growth in the TYK2 ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dhcNQjHv6E4p246dydUpYw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7b0670e7da8c4cb8c5e36ff60eee0742","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dhcNQjHv6E4p246dydUpYw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7b0670e7da8c4cb8c5e36ff60eee0742"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-investigational-lead-candidate-supports-183211063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","LU2242652126.USD","LU0321505439.SGD","LU0882574055.USD","LU1718418525.SGD","LU0306806265.USD","IE0002141913.USD","LU1291159041.SGD","BK4581","LU2133065610.SGD","LU1670711123.USD","IE00BFTCPJ56.SGD","LU2125154935.USD","LU2360032135.SGD","BK4588","LU1670710661.SGD","LU0985481810.HKD","TAK","IE00B2B36J28.USD","MYE","LU0225284248.USD","LU1261432733.SGD","LU1093756168.USD","LU1571399168.USD","LU1670710588.SGD","BK4077","LU0456855351.SGD","LU2242646821.SGD","BK4532","LU1989771016.USD","LU0061475181.USD","BK4126","BK4534","BK4007","LU0225771236.USD","LU0306807586.USD","BK4585","LU1670711040.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU1074936037.SGD","LU1093756325.SGD","SLE","LU1032466523.USD","BMY","LU1585245621.USD","LU2125154778.USD","LU0321505868.SGD","ALMS","LU0868494617.USD"],"gpt_icon":0},{"id":"2476404351","title":"HC Wainwright Initiates Coverage on Alumis With Buy Rating, $30 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2476404351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476404351?lang=en_us&edition=fundamental","pubTime":"2024-10-17 20:08","pubTimestamp":1729166922,"startTime":"0","endTime":"0","summary":"Price: 12.00, Change: +0.81, Percent Change: +7.24","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS"],"gpt_icon":0},{"id":"2476112658","title":"Alumis initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2476112658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476112658?lang=en_us&edition=fundamental","pubTime":"2024-10-17 18:11","pubTimestamp":1729159873,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Alumis with a Buy rating and $30 price target Alumis is a clinical-stage biopharmaceu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-initiated-with-a-buy-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2476452114","title":"Alumis Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2476452114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476452114?lang=en_us&edition=fundamental","pubTime":"2024-10-17 18:05","pubTimestamp":1729159547,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nAZN2G2AO6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2474046714","title":"Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'","url":"https://stock-news.laohu8.com/highlight/detail?id=2474046714","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474046714?lang=en_us&edition=fundamental","pubTime":"2024-10-10 19:00","pubTimestamp":1728558017,"startTime":"0","endTime":"0","summary":"Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Target Corporation  right here. “I'm going to buy some Target at this price and then wait another five points and buy more,” he noted.On Sept. 19, Target tapped PepsiCo, Inc‘s  Jim Lee as its CFO and a member of its leadership team, which became effective Sept. 22. Lee brings over 25 years of experience in finance, strategy and more at PepsiCo. He takes over from COO Michael Fiddelke. Lee has served on multiple boards during his PepsiCo career, including Tropicana Brands Group and Celsius Holdings.This billion-dollar fund has invested in the next big real estate boom, here's how you can join for $10.This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them c","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Tf3l5mg63oVE2crdiWPGFg--~B/aD00ODA7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/benzinga_79/97d978879da6717430718561468b1d6a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Tf3l5mg63oVE2crdiWPGFg--~B/aD00ODA7dz03MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/benzinga_79/97d978879da6717430718561468b1d6a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-says-hes-buying-110017108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765489.SGD","LU1934455863.HKD","TGT","SQQQ","BK4581","LU0208291251.USD","LU0052756011.USD","QID","MRK","LU1917777945.USD","IE00BN8TJ469.HKD","IE00B2B36J28.USD","LU1244550577.SGD","IE00B3T34201.USD","LU0266013472.USD","BK4533","QLD","IE00BJJMRZ35.SGD","ALMS","LU0234572021.USD","LU1066051225.USD","BK4114","BK4588","LU1037948541.HKD","PSQ","IE00B4R5TH58.HKD","IE0002141913.USD","PEP","LU0965509010.AUD","LU0310799852.SGD","LU0211328371.USD","TQQQ","LU0006306889.USD","LU1585245621.USD","BK4559","LU2237443622.USD","SOUN","LU1894683348.USD","LU0203347892.USD","U","LU2237443978.SGD","IE00BSNM7G36.USD","LU0265550946.USD","MNQmain","LU0211327993.USD","BK4587","LU1023059063.AUD",".IXIC","LU1291159041.SGD","NQmain"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":93}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-03","current":-1.819538,"percent":0.666667,"low":-5.220865,"twenty":-3.506511,"median":-2.145313,"eighty":-1.31069,"high":-0.660137,"avg":-2.454452,"sd":1.052408,"marketCap":535368097},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-03","current":-1.819538,"twenty":-3.506511,"median":-2.145313,"eighty":-1.31069,"marketCap":535368097}],"updateTime":1743799980646}}}